AUTHOR=Lin Shih-Yi , Hsu Wu-Huei , Lin Cheng-Chieh , Lin Cheng-Li , Tsai Chun-Hao , Yeh Hung-Chieh , Hsu Chung-Y. , Kao Chia-Hung 

TITLE=Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

JOURNAL=Frontiers in Pharmacology

VOLUME=9

YEAR=2018

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00677

DOI=10.3389/fphar.2018.00677

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture.</p><p><bold>Methods:</bold> The sitagliptin cohort included 1,578 patients aged 20 years and above. The nonsitagliptin cohort comprised propensity-score matched patients at a ratio of 1:1. The primary outcome was the incidence of fractures, which was evaluated using Kaplan–Meier survival analysis and proportional hazards modeling.</p><p><bold>Results:</bold> The mean age of patients in the sitagliptin and nonsitagliptin cohorts was 63.1 and 63.3 years, respectively. The incidence of fractures in the sitagliptin cohort was 46 per 1,000 person-years and that in the nonsitagliptin cohort was 40.8 per 1,000 person-years. Compared with patients in the nonsitagliptin cohort, those in the sitagliptin cohort who received sitagliptin for ≥250 days had a higher risk of fracture (aHR = 1.32, 95% CI = 1.06–1.64).</p><p><bold>Conclusion:</bold> Using sitaglipin ≥250 days was associated with an increased risk of fracture.</p>